Abstract
Background and aims: Sorafenib (SOR) is currently used in hepatocellular carcinoma (HCC) recurring after liver transplantation (LT), generally when surgical/locoregional treatments are excluded. The early introduction of SOR after HCC-recurrence and its association with mTOR-inhibitors (mTORi) are still debated. We evaluated safety and effectiveness of SOR with or without mTORi (SOR ± mTORi) in this setting.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
